| Identification | Back Directory | [Name]
PRLX93936 rastin analogue | [CAS]
903499-49-0 | [Synonyms]
PRLX-93936
PRLX93936,PRLX 93936
PRLX93936 rastin analogue
4(3H)-Quinazolinone, 3-(2-ethoxyphenyl)-2-(1-piperazinylmethyl)- | [Molecular Formula]
C21H24N4O2 | [MDL Number]
MFCD18633228 | [MOL File]
903499-49-0.mol | [Molecular Weight]
364.44 |
| Chemical Properties | Back Directory | [Boiling point ]
545.5±60.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: Soluble | [form ]
A solid | [pka]
9.01±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma[1][2]. | [References]
[1] Huang W, et al. Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5239-43. DOI:10.1016/j.bmcl.2011.07.043
[2] Voorhees P M, et al. An open-label, dose escalation, multi-center phase 1 study of PRLX 93936, an agent synthetically active against the activated ras pathway, in the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Blood, 2014, 124(21): 2140. |
|
|